The effect of olokizumab on rheumatoid arthritis patient’s reported outcomes: results of a double-blind randomized placebo-controlled multicenter phase III trial (CREDO 1)

The effect of olokizumab on rheumatoid arthritis patient’s reported outcomes: results of a double-blind randomized placebo-controlled multicenter phase III trial (CREDO 1)

Background. Olokizumab is a new interleukin-6 (IL-6) inhibitor that has demonstrated good efficacy and safety for the treatment of adult patients with moderate to high-grade activity of rheumatoid arthritis in combination with methotrexate with insufficient efficacy of methotrexate monotherapy.Aim o...

Full description

Bibliographic Details
Main Authors: E. L. Nasonov, T. A. Lisitsyna, E. V. Zonova, S. M. Kuzkina
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2021-03-01
Series:Научно-практическая ревматология
Subjects:
rheumatoid arthritis
il-6 inhibitors
olokizumab
credo 1
patient’s reported outcomes
Online Access:https://rsp.mediar-press.net/rsp/article/view/2991

Internet

https://rsp.mediar-press.net/rsp/article/view/2991

Similar Items